» Articles » PMID: 6161885

Release of Platelet-activating Factor (PAF) and Histamine. II. The Cellular Origin of Human PAF: Monocytes, Polymorphonuclear Neutrophils and Basophils

Overview
Journal Immunology
Date 1981 Feb 1
PMID 6161885
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

The origin of platelet activating factor (PAF) from human leucocytes was investigated. Purified monocytes release PAF passively at pH 10.6, when challenged with Ionophore A 23187 or under phagocytic stimuli. Pure preparations of polymorphonuclear neutrophils liberate PAF passively, when challenged with C5a, neutrophil cationic proteins (CP), their carboxypeptidase B derived products (C5a des Arg, CP des Arg) or under phagocytic stimuli. Basophil rich buffy coat cells release PAF when challenged with C5a, CP, anti-IgE (in low amount) or Synacthen concomitantly with basophil degranulation and histamine release. Electron microscopy studies, carried out on Synacthen-stimulated basophil rich buffy coat, provide morphological evidence for platelet-basophil interaction. In conclusion our data demonstrate that PAF can be released from different leucocyte populations. However, the stimuli able to trigger such release appear to have some specificity for the cell target.

Citing Articles

Importance of mast cell histamine secretion in IgG-mediated systemic anaphylaxis.

Khodoun M, Strait R, Hall A, Stolfi A, Finkelman F J Allergy Clin Immunol. 2024; 155(3):956-973.

PMID: 39550048 PMC: 11875995. DOI: 10.1016/j.jaci.2024.11.009.


IgG subclasses determine pathways of anaphylaxis in mice.

Beutier H, Gillis C, Iannascoli B, Godon O, England P, Sibilano R J Allergy Clin Immunol. 2016; 139(1):269-280.e7.

PMID: 27246523 PMC: 5081282. DOI: 10.1016/j.jaci.2016.03.028.


Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells.

Puebla-Osorio N, Damiani E, Bover L, Ullrich S Cell Death Dis. 2015; 6:e1745.

PMID: 25950475 PMC: 4669695. DOI: 10.1038/cddis.2015.115.


Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury.

Bitencourt C, Bessi V, Huynh D, Menard L, Lefebvre J, Levesque T J Cell Mol Med. 2013; 17(12):1554-65.

PMID: 24373549 PMC: 3914641. DOI: 10.1111/jcmm.12118.


Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis.

Khodoun M, Kucuk Z, Strait R, Krishnamurthy D, Janek K, Clay C J Allergy Clin Immunol. 2013; 132(6):1375-87.

PMID: 24139828 PMC: 8215526. DOI: 10.1016/j.jaci.2013.09.008.


References
1.
Chignard M, Le Couedic J, Tence M, Vargaftig B, Benveniste J . The role of platelet-activating factor in platelet aggregation. Nature. 1979; 279(5716):799-800. DOI: 10.1038/279799a0. View

2.
Camussi G, Tetta C, Segoloni G, Vercellone A . Immunological mechanisms of human platelet involvement. Ric Clin Lab. 1978; 8(4):262-72. View

3.
Mencia-Huerta J, Benveniste J . Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol. 1979; 9(5):409-15. DOI: 10.1002/eji.1830090512. View

4.
Demopoulos C, Pinckard R, HANAHAN D . Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979; 254(19):9355-8. View

5.
Lotner G, Lynch J, Betz S, Henson P . Human neutrophil-derived platelet activating factor. J Immunol. 1980; 124(2):676-84. View